CNS Pharmaceuticals Files 8-K Report

Ticker: CNSP · Form: 8-K · Filed: 2025-07-15T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, 8-K, disclosure

TL;DR

CNS Pharmaceuticals filed a routine 8-K, no major news yet.

AI Summary

On July 15, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt, but it confirms the company's ongoing reporting obligations.

Why It Matters

This filing indicates CNS Pharmaceuticals, Inc. is meeting its regulatory disclosure requirements with the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — This filing is a standard regulatory disclosure and does not contain new material information that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for CNS Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the filing details.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on July 15, 2025.

In which state is CNS Pharmaceuticals, Inc. incorporated?

CNS Pharmaceuticals, Inc. is incorporated in Nevada.

What is the business address of CNS Pharmaceuticals, Inc.?

The business address of CNS Pharmaceuticals, Inc. is 2100 West Loop South, Suite 900, Houston, Texas 77027.

What is the SIC code for CNS Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for CNS Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001683168-25-005129.txt : 20250715 0001683168-25-005129.hdr.sgml : 20250715 20250715171952 ACCESSION NUMBER: 0001683168-25-005129 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 33 CONFORMED PERIOD OF REPORT: 20250715 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250715 DATE AS OF CHANGE: 20250715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 251125669 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 8-K 1 cns_8k.htm FORM 8-K 8-K false 0001729427 0001729427 2025-07-15 2025-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 15, 2025 ___________________________   CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ___________________________   Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)   2100 West Loop South , Suite 900 Houston , Texas 77027 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (800) 946-9185   Not Applicable (Former Name or Former Address, if Changed Since Last Report) ___________________________   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbols(s) Name of each exchange on which registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Market LLC               Item 7.01. Regulation FD Disclosure.   On July 15, 2025, CNS Pharmaceuticals, Inc. (the “Company”) posted the investor presentation set forth in Exhibit 99.1 on its website.   The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be “filed” for the purpose of the Securities Exc

View on Read The Filing